FindTrial
Sign In

Application and evaluation of ultrasound optimized treatment in the management of cardiogenic shock patients with ECMO

Application and evaluation of ultrasound optimized treatment in the management of cardiogenic shock patients with ECMO

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057147
Enrollment
Unknown
Registered
2022-03-01
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic shock

Interventions

Control group:Traditional experience
Experimental group:Ultrasonic optimization

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with severe and reversible cardiogenic shock requiring ECMO support; 2. Aged 18-65 years; 3. The patient or the authorized agent signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Confirmed or suspected patients with nerve injury; 2. Serious primary diseases affecting survival: malignant tumors with multiple metastases that cannot be resected, hematologic diseases, HIV, etc.; 3. Patients deemed unsuitable for inclusion by the competent doctor.

Design outcomes

Primary

MeasureTime frame
28-day survival rate;Bleeding complications;Thrombotic complications;—

Countries

China

Contacts

Public ContactSun Bin

Xuzhou Central Hospital

sun_bin66@163.com+86 15852152417

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026